Yahoo Finance • 9 days ago
The small cap-focused Russell 2000 index has spent years lagging behind the larger S&P 500 and Nasdaq 100 indexes, but in third-quarter 2025 it took a big leap back to parity with large caps. Thanks to interest-rate-cut bets and optimism... Full story
Yahoo Finance • last month
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of Septem... Full story
Yahoo Finance • last month
[Small Cap write on sticky notes isolated on Office Desk. Stock market concept] syahrir maulana/iStock via Getty Images The Russell 2000 (IMW) is close to its strongest relative performance compared to the S&P 500 (SP500 [https://seekinga... Full story
Yahoo Finance • 4 months ago
[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer In the aftermath of several dea... Full story
Yahoo Finance • 6 months ago
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly... Full story
Yahoo Finance • 7 months ago
—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan... Full story
Yahoo Finance • 7 months ago
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly... Full story
Yahoo Finance • 7 months ago
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly p... Full story